The prognostic significance of age in surgically staged patients with Type II endometrial carcinoma

Sean Vance, Raphael Yechieli, Chad Cogan, Rabbie Hanna, Adnan Munkarah, Mohamed A. Elshaikh

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objective: Many studies have examined the impact of older age on tumor recurrence and survival after hysterectomy for patients with endometrioid carcinoma. However, there is paucity of data examining the prognostic significance of age in patients with Type II endometrial carcinoma. The study was conducted to determine the prognostic impact of age in this patient population. Materials and methods: In this Institutional Review Board (IRB)-approved study, our prospectively-maintained database of 1305 patients with endometrial cancer was reviewed. Seventy-two consecutive patients with serous and clear carcinoma 2009 FIGO stages I-II were identified with at least one year follow-up after surgical staging. Patients with mixed histology and those who received preoperative therapy were excluded. All the patients underwent surgical staging from 1989 to 2009. Their medical records were reviewed. The study cohort was divided into two groups based on their age at hysterectomy (≤ 65 vs. > 65). Patient's demographics, pathologic features and treatment-related factors were compared. The impact of age on recurrence-free survival (RFS), disease-specific survival (DSS) and overall survival (OS) were calculated. Following univariate analysis, multivariate modeling was done using step-wise Cox proportional hazards analysis to assess the impact of age on clinical outcomes after adjusting for various clinical variables. Results: Median follow-up for the study cohort was 45 months (range 13-246). Fifty percent of patients received adjuvant platinum-based chemotherapy and/or adjuvant radiation treatment (RT). Thirty-five patients were older than 65 years (49%) and 37 were ≤ 65 (51%). There were no significant differences between the two groups in regard to race (African American vs Caucasian), FIGO stage, number of lymph nodes dissected, lymphovascular space involvement (LVSI), or adjuvant therapy received. There were more clear cell histology in the younger age group (p = 0.035). Patients > 65 years old developed more recurrences with a 5-year RFS of 59% compared to 84% for younger patients (p = 0.036). The five-year DSS was not statistically different between the two groups (68% vs. 79%, respectively with p = 0.313). 5-year OS was significantly shorter in the elderly patients (58% vs. 78% with p = 0.014). On multivariate analysis, the presence of LVSI, not receiving RT and age > 65 were independent predictors of worse RFS (p = < 0.001, 0.005, and 0.040 respectively). Conclusion: In this study for surgically staged FIGO I-II patients with Type II endometrial carcinoma, age more than 65 years is a significant adverse prognostic factor for tumor recurrence.

Original languageEnglish (US)
Pages (from-to)16-19
Number of pages4
JournalGynecologic Oncology
Volume126
Issue number1
DOIs
StatePublished - Jul 2012
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Survival
Recurrence
Hysterectomy
Histology
Radiation
Endometrioid Carcinoma
Therapeutics
Research Ethics Committees
Adjuvant Chemotherapy
Platinum
African Americans
Disease-Free Survival
Medical Records
Neoplasms
Cohort Studies
Multivariate Analysis
Age Groups
Lymph Nodes

Keywords

  • Clear
  • Endometrial carcinoma
  • Old age
  • Prognosis
  • Serous
  • Type II

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

The prognostic significance of age in surgically staged patients with Type II endometrial carcinoma. / Vance, Sean; Yechieli, Raphael; Cogan, Chad; Hanna, Rabbie; Munkarah, Adnan; Elshaikh, Mohamed A.

In: Gynecologic Oncology, Vol. 126, No. 1, 07.2012, p. 16-19.

Research output: Contribution to journalArticle

Vance, Sean ; Yechieli, Raphael ; Cogan, Chad ; Hanna, Rabbie ; Munkarah, Adnan ; Elshaikh, Mohamed A. / The prognostic significance of age in surgically staged patients with Type II endometrial carcinoma. In: Gynecologic Oncology. 2012 ; Vol. 126, No. 1. pp. 16-19.
@article{51851a7799d441f192377a819ac6acef,
title = "The prognostic significance of age in surgically staged patients with Type II endometrial carcinoma",
abstract = "Objective: Many studies have examined the impact of older age on tumor recurrence and survival after hysterectomy for patients with endometrioid carcinoma. However, there is paucity of data examining the prognostic significance of age in patients with Type II endometrial carcinoma. The study was conducted to determine the prognostic impact of age in this patient population. Materials and methods: In this Institutional Review Board (IRB)-approved study, our prospectively-maintained database of 1305 patients with endometrial cancer was reviewed. Seventy-two consecutive patients with serous and clear carcinoma 2009 FIGO stages I-II were identified with at least one year follow-up after surgical staging. Patients with mixed histology and those who received preoperative therapy were excluded. All the patients underwent surgical staging from 1989 to 2009. Their medical records were reviewed. The study cohort was divided into two groups based on their age at hysterectomy (≤ 65 vs. > 65). Patient's demographics, pathologic features and treatment-related factors were compared. The impact of age on recurrence-free survival (RFS), disease-specific survival (DSS) and overall survival (OS) were calculated. Following univariate analysis, multivariate modeling was done using step-wise Cox proportional hazards analysis to assess the impact of age on clinical outcomes after adjusting for various clinical variables. Results: Median follow-up for the study cohort was 45 months (range 13-246). Fifty percent of patients received adjuvant platinum-based chemotherapy and/or adjuvant radiation treatment (RT). Thirty-five patients were older than 65 years (49{\%}) and 37 were ≤ 65 (51{\%}). There were no significant differences between the two groups in regard to race (African American vs Caucasian), FIGO stage, number of lymph nodes dissected, lymphovascular space involvement (LVSI), or adjuvant therapy received. There were more clear cell histology in the younger age group (p = 0.035). Patients > 65 years old developed more recurrences with a 5-year RFS of 59{\%} compared to 84{\%} for younger patients (p = 0.036). The five-year DSS was not statistically different between the two groups (68{\%} vs. 79{\%}, respectively with p = 0.313). 5-year OS was significantly shorter in the elderly patients (58{\%} vs. 78{\%} with p = 0.014). On multivariate analysis, the presence of LVSI, not receiving RT and age > 65 were independent predictors of worse RFS (p = < 0.001, 0.005, and 0.040 respectively). Conclusion: In this study for surgically staged FIGO I-II patients with Type II endometrial carcinoma, age more than 65 years is a significant adverse prognostic factor for tumor recurrence.",
keywords = "Clear, Endometrial carcinoma, Old age, Prognosis, Serous, Type II",
author = "Sean Vance and Raphael Yechieli and Chad Cogan and Rabbie Hanna and Adnan Munkarah and Elshaikh, {Mohamed A.}",
year = "2012",
month = "7",
doi = "10.1016/j.ygyno.2012.04.011",
language = "English (US)",
volume = "126",
pages = "16--19",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The prognostic significance of age in surgically staged patients with Type II endometrial carcinoma

AU - Vance, Sean

AU - Yechieli, Raphael

AU - Cogan, Chad

AU - Hanna, Rabbie

AU - Munkarah, Adnan

AU - Elshaikh, Mohamed A.

PY - 2012/7

Y1 - 2012/7

N2 - Objective: Many studies have examined the impact of older age on tumor recurrence and survival after hysterectomy for patients with endometrioid carcinoma. However, there is paucity of data examining the prognostic significance of age in patients with Type II endometrial carcinoma. The study was conducted to determine the prognostic impact of age in this patient population. Materials and methods: In this Institutional Review Board (IRB)-approved study, our prospectively-maintained database of 1305 patients with endometrial cancer was reviewed. Seventy-two consecutive patients with serous and clear carcinoma 2009 FIGO stages I-II were identified with at least one year follow-up after surgical staging. Patients with mixed histology and those who received preoperative therapy were excluded. All the patients underwent surgical staging from 1989 to 2009. Their medical records were reviewed. The study cohort was divided into two groups based on their age at hysterectomy (≤ 65 vs. > 65). Patient's demographics, pathologic features and treatment-related factors were compared. The impact of age on recurrence-free survival (RFS), disease-specific survival (DSS) and overall survival (OS) were calculated. Following univariate analysis, multivariate modeling was done using step-wise Cox proportional hazards analysis to assess the impact of age on clinical outcomes after adjusting for various clinical variables. Results: Median follow-up for the study cohort was 45 months (range 13-246). Fifty percent of patients received adjuvant platinum-based chemotherapy and/or adjuvant radiation treatment (RT). Thirty-five patients were older than 65 years (49%) and 37 were ≤ 65 (51%). There were no significant differences between the two groups in regard to race (African American vs Caucasian), FIGO stage, number of lymph nodes dissected, lymphovascular space involvement (LVSI), or adjuvant therapy received. There were more clear cell histology in the younger age group (p = 0.035). Patients > 65 years old developed more recurrences with a 5-year RFS of 59% compared to 84% for younger patients (p = 0.036). The five-year DSS was not statistically different between the two groups (68% vs. 79%, respectively with p = 0.313). 5-year OS was significantly shorter in the elderly patients (58% vs. 78% with p = 0.014). On multivariate analysis, the presence of LVSI, not receiving RT and age > 65 were independent predictors of worse RFS (p = < 0.001, 0.005, and 0.040 respectively). Conclusion: In this study for surgically staged FIGO I-II patients with Type II endometrial carcinoma, age more than 65 years is a significant adverse prognostic factor for tumor recurrence.

AB - Objective: Many studies have examined the impact of older age on tumor recurrence and survival after hysterectomy for patients with endometrioid carcinoma. However, there is paucity of data examining the prognostic significance of age in patients with Type II endometrial carcinoma. The study was conducted to determine the prognostic impact of age in this patient population. Materials and methods: In this Institutional Review Board (IRB)-approved study, our prospectively-maintained database of 1305 patients with endometrial cancer was reviewed. Seventy-two consecutive patients with serous and clear carcinoma 2009 FIGO stages I-II were identified with at least one year follow-up after surgical staging. Patients with mixed histology and those who received preoperative therapy were excluded. All the patients underwent surgical staging from 1989 to 2009. Their medical records were reviewed. The study cohort was divided into two groups based on their age at hysterectomy (≤ 65 vs. > 65). Patient's demographics, pathologic features and treatment-related factors were compared. The impact of age on recurrence-free survival (RFS), disease-specific survival (DSS) and overall survival (OS) were calculated. Following univariate analysis, multivariate modeling was done using step-wise Cox proportional hazards analysis to assess the impact of age on clinical outcomes after adjusting for various clinical variables. Results: Median follow-up for the study cohort was 45 months (range 13-246). Fifty percent of patients received adjuvant platinum-based chemotherapy and/or adjuvant radiation treatment (RT). Thirty-five patients were older than 65 years (49%) and 37 were ≤ 65 (51%). There were no significant differences between the two groups in regard to race (African American vs Caucasian), FIGO stage, number of lymph nodes dissected, lymphovascular space involvement (LVSI), or adjuvant therapy received. There were more clear cell histology in the younger age group (p = 0.035). Patients > 65 years old developed more recurrences with a 5-year RFS of 59% compared to 84% for younger patients (p = 0.036). The five-year DSS was not statistically different between the two groups (68% vs. 79%, respectively with p = 0.313). 5-year OS was significantly shorter in the elderly patients (58% vs. 78% with p = 0.014). On multivariate analysis, the presence of LVSI, not receiving RT and age > 65 were independent predictors of worse RFS (p = < 0.001, 0.005, and 0.040 respectively). Conclusion: In this study for surgically staged FIGO I-II patients with Type II endometrial carcinoma, age more than 65 years is a significant adverse prognostic factor for tumor recurrence.

KW - Clear

KW - Endometrial carcinoma

KW - Old age

KW - Prognosis

KW - Serous

KW - Type II

UR - http://www.scopus.com/inward/record.url?scp=84862765875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862765875&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2012.04.011

DO - 10.1016/j.ygyno.2012.04.011

M3 - Article

C2 - 22507535

AN - SCOPUS:84862765875

VL - 126

SP - 16

EP - 19

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -